Get the Stockscreener App
3.25
7.97%
0.24
Pre-market:
3.12
-0.13
-4.00%
Sab Biotherapeutics Inc stock is traded at $3.25, with a volume of 220.61K.
It is up +7.97% in the last 24 hours and up +61.69% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$3.01
Open:
$2.93
24h Volume:
220.61K
Relative Volume:
0.96
Market Cap:
$33.84M
Revenue:
$114.70K
Net Income/Loss:
$-37.06M
P/E Ratio:
-0.8139
EPS:
-3.9929
Net Cash Flow:
$-30.69M
1W Performance:
+7.26%
1M Performance:
+61.69%
6M Performance:
+91.18%
1Y Performance:
-0.31%
1-Day Range:
$2.93
$3.33
1-Week Range:
$2.9001
$3.33
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.25 | 31.34M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
Why retail investors pile into SAB Biotherapeutics Inc. stockJuly 2025 Final Week & Capital Protection Trading Alerts - newser.com
Is SAB Biotherapeutics Inc. Equity Warrant reversing from oversold territoryPortfolio Value Report & Real-Time Market Trend Scan - newser.com
Published on: 2025-11-03 02:45:13 - newser.com
Published on: 2025-11-03 01:49:06 - newser.com
Quantitative breakdown of SAB Biotherapeutics Inc. Equity Warrant recent moveTrade Volume Summary & Growth Focused Stock Reports - newser.com
Why SAB Biotherapeutics Inc. Equity Warrant stock remains on buy listsQuarterly Growth Report & Accurate Trade Setup Notifications - newser.com
Why SAB Biotherapeutics Inc. Equity Warrant stock remains undervaluedWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Published on: 2025-11-02 20:28:45 - newser.com
Will SAB Biotherapeutics Inc. rebound enough to break evenPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com
What analysts say about SAB Biotherapeutics Inc stockFlag and Pennant Patterns & Free Daily Stock Hotspot Analysis - earlytimes.in
Using data filters to optimize entry into SAB Biotherapeutics Inc. Equity WarrantLong Setup & Real-Time Buy Signal Notifications - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant stock keep outperforming rivalsCPI Data & Stock Portfolio Risk Management - newser.com
Is SAB Biotherapeutics Inc. Equity Warrant a candidate for recovery play2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com
What hedge fund activity signals for SAB Biotherapeutics Inc. stockShare Buyback & Free Daily Entry Point Trade Alerts - newser.com
How SAB Biotherapeutics Inc. Equity Warrant stock benefits from global expansionWeekly Investment Summary & AI Optimized Trading Strategy Guides - newser.com
Can SAB Biotherapeutics Inc. Equity Warrant stock resist sector downturns2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
Will SAB Biotherapeutics Inc. stock maintain dividend yield2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Ranking SAB Biotherapeutics Inc. Equity Warrant among high performing stocks via toolsMarket Activity Summary & Daily Technical Stock Forecast Reports - newser.com
Trend analysis for SAB Biotherapeutics Inc. Equity Warrant this weekWeekly Investment Summary & AI Optimized Trading Strategy Guides - newser.com
What insider trading reveals about SAB Biotherapeutics Inc. Equity Warrant stockJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Custom strategy builders for tracking SAB Biotherapeutics Inc. Equity WarrantMarket Performance Report & Free Accurate Trade Setup Notifications - newser.com
Is SAB Biotherapeutics Inc. forming a reversal patternStop Loss & Accurate Trade Setup Notifications - newser.com
Can trapped investors hope for a rebound in SAB Biotherapeutics Inc.Quarterly Investment Review & Real-Time Volume Spike Alerts - newser.com
Will SAB Biotherapeutics Inc. stock deliver consistent dividendsJuly 2025 Decliners & Stepwise Swing Trade Plans - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant stock benefit from sector rotation2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
How SAB Biotherapeutics Inc. Equity Warrant stock performs in interest rate cyclesJuly 2025 Update & AI Driven Stock Reports - newser.com
Published on: 2025-11-01 03:46:19 - newser.com
Tick level data insight on SAB Biotherapeutics Inc. volatilityQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
How to build a custom watchlist for SAB Biotherapeutics Inc. Equity WarrantWeekly Volume Report & AI Driven Price Forecasts - newser.com
Will SAB Biotherapeutics Inc. stock see PE expansionWeekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Using Python tools to backtest SAB Biotherapeutics Inc. Equity Warrant strategiesJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Can SAB Biotherapeutics Inc. Equity Warrant stock deliver surprise earnings beatJuly 2025 Retail & Safe Capital Preservation Plans - newser.com
Real time pattern detection on SAB Biotherapeutics Inc. Equity Warrant stockTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sab Biotherapeutics Inc Stock (SABS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):